vs
Side-by-side financial comparison of Amneal Pharmaceuticals, Inc. (AMRX) and OGE ENERGY CORP. (OGE). Click either name above to swap in a different company.
OGE ENERGY CORP. is the larger business by last-quarter revenue ($752.6M vs $722.5M, roughly 1.0× Amneal Pharmaceuticals, Inc.). Amneal Pharmaceuticals, Inc. runs the higher net margin — 10.8% vs 6.7%, a 4.1% gap on every dollar of revenue. On growth, Amneal Pharmaceuticals, Inc. posted the faster year-over-year revenue change (3.9% vs 0.7%). Over the past eight quarters, OGE ENERGY CORP.'s revenue compounded faster (8.1% CAGR vs 1.5%).
Amneal Pharmaceuticals, Inc. is an American publicly traded pharmaceutical company that develops, manufactures and distributes generics and specialty pharmaceutical products. The company is headquartered in Bridgewater, New Jersey, and is one of the largest manufacturers of generic drugs in the United States.
Oklahoma Gas & Electric Company is a regulated electric utility company that serves over 843,000 customers in Oklahoma and Arkansas, including 1.5 million people in the Oklahoma City Metropolitan Area. It is the leading subsidiary of OGE Energy Corp., with headquarters in downtown Oklahoma City. OGE Energy is also the former parent of Enogex Inc., a natural gas pipeline business which merged with CenterPoint Energy's midstream business to form Enable Midstream in 2013, in 2021 OGE and CenterP...
AMRX vs OGE — Head-to-Head
Income Statement — Q1 FY2026 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $722.5M | $752.6M |
| Net Profit | $78.0M | $50.2M |
| Gross Margin | 44.3% | — |
| Operating Margin | — | 15.0% |
| Net Margin | 10.8% | 6.7% |
| Revenue YoY | 3.9% | 0.7% |
| Net Profit YoY | 217.0% | -19.9% |
| EPS (diluted) | $0.19 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $722.5M | $752.6M | ||
| Q4 25 | $814.3M | $701.7M | ||
| Q3 25 | $784.5M | $1.0B | ||
| Q2 25 | $724.5M | $719.7M | ||
| Q1 25 | $695.4M | $741.1M | ||
| Q4 24 | $730.5M | $744.7M | ||
| Q3 24 | $702.5M | $945.2M | ||
| Q2 24 | $701.8M | $644.1M |
| Q1 26 | $78.0M | $50.2M | ||
| Q4 25 | $35.1M | $69.2M | ||
| Q3 25 | $2.4M | $231.3M | ||
| Q2 25 | $22.4M | $107.5M | ||
| Q1 25 | $12.2M | $62.7M | ||
| Q4 24 | $-31.1M | $101.9M | ||
| Q3 24 | $-156.0K | $218.7M | ||
| Q2 24 | $6.0M | $102.3M |
| Q1 26 | 44.3% | — | ||
| Q4 25 | 36.5% | 59.2% | ||
| Q3 25 | 34.9% | 62.2% | ||
| Q2 25 | 39.5% | 63.7% | ||
| Q1 25 | 36.8% | 56.3% | ||
| Q4 24 | 36.0% | 59.7% | ||
| Q3 24 | 38.4% | 63.0% | ||
| Q2 24 | 35.6% | 69.9% |
| Q1 26 | — | 15.0% | ||
| Q4 25 | 13.8% | 19.7% | ||
| Q3 25 | 9.0% | 33.2% | ||
| Q2 25 | 15.4% | 25.9% | ||
| Q1 25 | 14.4% | 18.0% | ||
| Q4 24 | 10.4% | 24.5% | ||
| Q3 24 | 12.6% | 33.1% | ||
| Q2 24 | 13.6% | 27.3% |
| Q1 26 | 10.8% | 6.7% | ||
| Q4 25 | 4.3% | 9.9% | ||
| Q3 25 | 0.3% | 22.5% | ||
| Q2 25 | 3.1% | 14.9% | ||
| Q1 25 | 1.8% | 8.5% | ||
| Q4 24 | -4.3% | 13.7% | ||
| Q3 24 | -0.0% | 23.1% | ||
| Q2 24 | 0.9% | 15.9% |
| Q1 26 | $0.19 | — | ||
| Q4 25 | $0.10 | $0.34 | ||
| Q3 25 | $0.01 | $1.14 | ||
| Q2 25 | $0.07 | $0.53 | ||
| Q1 25 | $0.04 | $0.31 | ||
| Q4 24 | $-0.10 | $0.50 | ||
| Q3 24 | $0.00 | $1.09 | ||
| Q2 24 | $0.02 | $0.51 |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AMRX
| Affordable Medicines net | $423.0M | 59% |
| AvKARE net | $166.0M | 23% |
| Specialty net | $133.0M | 18% |
OGE
| Residential | $260.4M | 35% |
| Commercial | $212.0M | 28% |
| Public authorities and street light | $61.9M | 8% |
| Industrial | $60.7M | 8% |
| Oilfield | $58.4M | 8% |
| Integrated market | $47.3M | 6% |
| Transmission | $40.7M | 5% |
